Search
What are you looking for?
Start main content
Dr CHIU Ka Fung Peter

Dr CHIU Ka Fung Peter

Assistant Dean, Translation and Entrepreneurship

Associate Professor, Department of Surgery

CUHK Employment
  • Assistant Dean (Translation and Entrepreneurship)
  • Associate Professor, SH Ho Urology Centre, Department of Surgery

 

Expertise
  • Urological Cancer
  • Endoscopic Surgery
  •  Minimally Invasive Surgery
  • Robotic Surgery

 

Education & Qualifications

MBChB (CUHK), PhD (EUR, Erasmus University Rotterdam), FRCSEd (Urol), FCSHK, FHKAM (Surgery)

 

 

Research Interests
  • Novel biomarkers for non-invasive prostate cancer diagnosis (prostate health index, urine spermine risk score, small non-coding RNA)
  • Transperineal MRI-Ultrasound fusion navigation-guided prostate biopsy
  • Automated AI-assisted MRI diagnosis of prostate cancer
  • Focal therapy for localized prostate cancer
  • Treatment for advanced prostate cancer
  • Novel treatments for Benign prostatic hyperplasia (BPH) including REZUM, Urolift, iTIND, targeted microwave ablation (TMA), laser vaporization

 

Additional Information

Award and Honour

  • Visiting Professorship, Department of Urology, Stanford University, 2024
  • Best paper, Hong Kong Urological Association ASM, 2009, 2021, 2024
  • Best paper in prostate cancer section, Urological Association of Asia, 2017
  • Top papers award, Journal Prostate Cancer and Prostatic Diseases, 2017

 

Professional Service

  • Associate member, European Association of Urology (EAU) Prostate Cancer Guidelines Panel
  • President, Hong Kong Urological Association (HKUA)
  • Member, Societe International Urologie (SIU) Scientific Program Committee
  • Member, Societe International Urologie (SIU) Research Council
  • Council member, Urological Association of Asian (UAA)
  • Board member, Hong Kong Kidney Foundation (HKKF)
  • Member, The College of Surgeons of Hong Kong (CSHK) Scientific Committee
  • Member, EAU Young Academic Urologists Prostate Cancer Working Group, 2021-2024
  • Editorial board member, International Journal of Urology
  • Editorial board member, Asian Journal of Andrology

 

Academic Engagement in CUHK

  • Faculty Board member, Faculty of Medicine
  • Coordinator, Year 6 Surgery subspecialty curriculum, Faculty of Medicine
  • Committee member, Joint CUHK-NTEC Clinical Research Ethics Committee (CREC)
  • Mentor, Global Physician Stream (GPS) Mentorship Scheme, Faculty of Medicine
  • Committee member, Student Exchange Committee, Wu Yee Sun College
Selected Publications

 

Researcher ID: https://www.webofscience.com/wos/author/record/AAY-2052-2020

 

  1. Chiu PK, Liu AQ, Yee CH, Wong HF, Chan CH, Kong A, Lau SY, Teoh JY, Lo KL, Yuen TY, Wong KH, Chu CM, Hung HY, Cho CC, Ng CF. Targeted Microwave Ablation for Prostate Cancer Under Magnetic Resonance Imaging-Ultrasound Fusion and Organ-based Tracking: Final Results from the First Phase 2 Trial (TMA-HK). Eur Urol Oncol. 2024 Dec 16:S2588-9311(24)00275-X. 
  2. Chiu PK, Ng CF, Semjonow A, Zhu Y, Vincendeau S, Houlgatte A, Lazzeri M, Guazzoni G, Stephan C, Haese A, Bruijne I, Teoh JY, Leung CH, Casale P, Chiang CH, Tan LG, Chiong E, Huang CY, Wu HC, Nieboer D, Ye DW, Bangma CH, Roobol MJ. A Multicentre Evaluation of the Role of the Prostate Health Index (PHI) in Regions with Differing Prevalence of Prostate Cancer: Adjustment of PHI Reference Ranges is Needed for European and Asian Settings. Eur Urol. 2019 Apr;75(4):558-561.
  3. Liu AQ, Remmers S, Lau SY, Yip SY, Leung CH, Mak CW, Yee CH, Teoh JY, Hou SM, Roobol M, Ng CF, Chiu PK. Initial Prostate Health Index (phi) and phi density predicts future risk of clinically significant prostate cancer in men with initial negative prostate biopsy: a 6-year follow-up study. Prostate Cancer Prostatic Dis. 2022 Apr;25(4):684-689
  4. He BM, Chiu PK, Tao T, Lan JH, Cai JT, Zhou SC, Li RB, Ren Y, Ka-Lun LO, Xu RY, Chen JR, Lan D, Gao JL, Chu SG, Jin ZC, Huang FF, Shi ZK, Yang QW, Zhou H, Wang SD, Ji TR, Han QP, Wang CM, Chi-Fai NG, Wang HF; APROPOS Group. Perineal nerve block versus periprostatic block for patients undergoing transperineal prostate biopsy (APROPOS): a prospective, multicentre, randomised controlled study. EClinicalMedicine. 2023 Mar 23;58:101919.
  5. Chiu PK, Lam, Thomas YT, Ng CF, Teoh JY, Cho CCM, Hung HY, Hong C, Roobol MJ, Chu WCW, Wong SY, Sung, JJY. The combined role of MRI prostate and prostate health index in improving detection of significant prostate cancer in a screening population of Chinese men. Asian Journal of Andrology ():10.4103/aja20239, May 02, 2023.
  6. Chiu PK, Leow JJ, Chiang CH, Mok A, Zhang K, Hsieh PF, Zhu Y, Lam W, Tsang WC, Fan YH, Lin TP, Chan TY, Leung CH, Teoh JY, Chu PS, Zhu G, Ye DW, Wu HC, Tan TW, Tsu JH, Ng CF, Chiong E, Huang CY. Prostate Health Index Density Outperforms Prostate-specific Antigen Density in the Diagnosis of Clinically Significant Prostate Cancer in Equivocal Magnetic Resonance Imaging of the Prostate: A Multicenter Evaluation. J Urol. 2023 Jul;210(1):88-98.
  7. Isotani S, Ka-Fung Chiu P, Ashizawa T, Fung YH, Ieda T, China T, Kawano H, Shimizu F, Nagata M, Nakagawa Y, Muto S, Wong KL, Ng CF, Horie S. Urine spermine and multiparametric magnetic resonance imaging for prediction of prostate cancer in Japanese men. Prostate Int. 2023 Sep;11(3):180-18 (co-first author)
  8. Wu X, Wu Y, Ng CF, Yee CH, Chiu PK. High-intensity focused ultrasound strategies for treating prostate cancer. Asian J Androl. 2024 Apr 26. (Corresponding author)
  9. Peng Q, Chen Y, Xie T, Pu D, Ho VW, Sun J, Liu K, Chan RC, Ding X, Teoh JY, Wang X, Chiu PK, Ng CF. PiRNA-4447944 promotes castration-resistant growth and metastasis of prostate cancer by inhibiting NEFH expression through forming the piRNA-4447944-PIWIL2-NEFH complex. Int J Biol Sci. 2024 Jul 1;20(9):3638-3655. (Co-corresponding author)
  10. Chiu PK, Liu AQ, Lau SY, Teoh JY, Ho CC, Yee CH, Hou SM, Chan CK, Tang WL, Bangma CH, Chu PS, Poon WT, Ng CF, Roobol MJ. A 2-year prospective evaluation of the Prostate Health Index in guiding biopsy decisions in a large cohort. BJU Int. 2024 Jul 4.